5/6 📌 Conclusion: LFCA embolization is a potentially viable midterm solution for hip pain reduction when conservative treatment and surgery aren't suitable.
🔗 Read more here: doi.org/doi:10.1007...
#HipPainManagement #VascularIntervention #MedTwitter #PainRelief #IR
🔗 Read more here: doi.org/doi:10.1007...
#HipPainManagement #VascularIntervention #MedTwitter #PainRelief #IR
Arterial Embolization of Joint Synovitis: The Latino Registry. Midterm Follow-Up of the Latino-Hip Cohort for Greater Trochanteric Pain Syndrome
CardioVascular and Interventional Radiology - To present the midterm follow-up of a cohort of 31 patients with great trochanteric pain syndrome (GTPS) refractory to conservative management or...
link.springer.com
March 13, 2025 at 12:00 PM
5/6 📌 Conclusion: LFCA embolization is a potentially viable midterm solution for hip pain reduction when conservative treatment and surgery aren't suitable.
🔗 Read more here: doi.org/doi:10.1007...
#HipPainManagement #VascularIntervention #MedTwitter #PainRelief #IR
🔗 Read more here: doi.org/doi:10.1007...
#HipPainManagement #VascularIntervention #MedTwitter #PainRelief #IR
3/6 Key Findings:
✅ Cumulative event rate significantly lower in PTAS group (11.6% vs. 34.9%, P=0.034)
✅ Median follow-up of 43 months
✅ No significant difference in ischemic strokes within 30 days or years 1-3, or secondary outcomes
#VascularIntervention
✅ Cumulative event rate significantly lower in PTAS group (11.6% vs. 34.9%, P=0.034)
✅ Median follow-up of 43 months
✅ No significant difference in ischemic strokes within 30 days or years 1-3, or secondary outcomes
#VascularIntervention
February 28, 2025 at 4:57 PM
3/6 Key Findings:
✅ Cumulative event rate significantly lower in PTAS group (11.6% vs. 34.9%, P=0.034)
✅ Median follow-up of 43 months
✅ No significant difference in ischemic strokes within 30 days or years 1-3, or secondary outcomes
#VascularIntervention
✅ Cumulative event rate significantly lower in PTAS group (11.6% vs. 34.9%, P=0.034)
✅ Median follow-up of 43 months
✅ No significant difference in ischemic strokes within 30 days or years 1-3, or secondary outcomes
#VascularIntervention
5/6 📌 Conclusion: In this study, LBAT demonstrated high technical success (95.8%) and favorable safety outcomes in octogenarians with PE, with low major complications and a 30-day mortality rate of 6.3%.
Full study: doi.org/doi:10.1186...
#VascularIntervention
Full study: doi.org/doi:10.1186...
#VascularIntervention
Large-bore aspiration thrombectomy for the treatment of pulmonary embolism in octogenarians - CVIR Endovascular
Purpose To evaluate outcomes in patients aged ≥ 80 years following large-bore aspiration thrombectomy (LBAT) for the treatment of pulmonary embolism (PE). Materials and methods All patients ≥ 80 years of age with PE treated via LBAT at a single center were analyzed from September 2019 – August 2024. This included the octogenarian subgroup from a recently published retrospective analysis assessing all PE patients treated with LBAT at our center between September 2019 and January 2023. The following outcomes were evaluated: technical success, change in several hemodynamic measures including pulmonary artery pressure (PAP) and right ventricle to left ventricle ratio (RV to LV ratio), length of hospital and intensive-care-unit (ICU) stay, procedure-related complications, and 7- and 30-day mortality. Results Forty-eight patients aged ≥ 80 years underwent LBAT procedures for PE. Technical success was achieved in 46 cases (95.8%). The mean reduction in mean PAP was 3.6 mmHg. The mean reductio
cvirendovasc.springeropen.com
February 15, 2025 at 5:22 PM
5/6 📌 Conclusion: In this study, LBAT demonstrated high technical success (95.8%) and favorable safety outcomes in octogenarians with PE, with low major complications and a 30-day mortality rate of 6.3%.
Full study: doi.org/doi:10.1186...
#VascularIntervention
Full study: doi.org/doi:10.1186...
#VascularIntervention
4/5 📌 Conclusion: These results supports Covera™ Stent’s safety & efficacy in managing AVF stenoses in real-world settings.
For in-depth insights, read the full study: doi.org/doi:10.1007...
#ClinicalResearch #VascularIntervention #Nephrology
For in-depth insights, read the full study: doi.org/doi:10.1007...
#ClinicalResearch #VascularIntervention #Nephrology
Six-Month Outcomes from the Prospective, Multi-Center, Non-Randomized Clinical Study of the COVERA(™) Arterio VeNous (AV) Stent Graft in the Treatment of Stenosis in the VEnous OutfloW of AV Fistula Access Circuits (AVeNEW PAS)
CardioVascular and Interventional Radiology - The AVeNEW Post-Approval Study (AVeNEW PAS) follows upon results from the AVeNEW IDE clinical trial and was designed to provide additional clinical...
link.springer.com
January 24, 2025 at 1:13 PM
4/5 📌 Conclusion: These results supports Covera™ Stent’s safety & efficacy in managing AVF stenoses in real-world settings.
For in-depth insights, read the full study: doi.org/doi:10.1007...
#ClinicalResearch #VascularIntervention #Nephrology
For in-depth insights, read the full study: doi.org/doi:10.1007...
#ClinicalResearch #VascularIntervention #Nephrology
3/6 Results Highlights:
✔️ 100% hemostasis success rate
✔️ No access-related complications observed
✔️ Mean manual compression time: 3.6 ± 1.2 min
✔️ Mean hemostasis time: 6.8 ± 1.4 min
✔️ 12.5% 30-day mortality rate
#PatientOutcomes #VascularIntervention
✔️ 100% hemostasis success rate
✔️ No access-related complications observed
✔️ Mean manual compression time: 3.6 ± 1.2 min
✔️ Mean hemostasis time: 6.8 ± 1.4 min
✔️ 12.5% 30-day mortality rate
#PatientOutcomes #VascularIntervention
January 20, 2025 at 9:01 PM
3/6 Results Highlights:
✔️ 100% hemostasis success rate
✔️ No access-related complications observed
✔️ Mean manual compression time: 3.6 ± 1.2 min
✔️ Mean hemostasis time: 6.8 ± 1.4 min
✔️ 12.5% 30-day mortality rate
#PatientOutcomes #VascularIntervention
✔️ 100% hemostasis success rate
✔️ No access-related complications observed
✔️ Mean manual compression time: 3.6 ± 1.2 min
✔️ Mean hemostasis time: 6.8 ± 1.4 min
✔️ 12.5% 30-day mortality rate
#PatientOutcomes #VascularIntervention
4/6 Additional Findings:
🔶 Chocolate balloons reduced flow-limiting dissection (p = 0.02)
🔶 Lower need for below-the-knee (BTK) stent implantation in chocolate balloon group (p = 0.03)
🔶 No significant improvement in AFS or major amputation reduction
#VascularIntervention #PAD
🔶 Chocolate balloons reduced flow-limiting dissection (p = 0.02)
🔶 Lower need for below-the-knee (BTK) stent implantation in chocolate balloon group (p = 0.03)
🔶 No significant improvement in AFS or major amputation reduction
#VascularIntervention #PAD
January 17, 2025 at 1:00 PM
4/6 Additional Findings:
🔶 Chocolate balloons reduced flow-limiting dissection (p = 0.02)
🔶 Lower need for below-the-knee (BTK) stent implantation in chocolate balloon group (p = 0.03)
🔶 No significant improvement in AFS or major amputation reduction
#VascularIntervention #PAD
🔶 Chocolate balloons reduced flow-limiting dissection (p = 0.02)
🔶 Lower need for below-the-knee (BTK) stent implantation in chocolate balloon group (p = 0.03)
🔶 No significant improvement in AFS or major amputation reduction
#VascularIntervention #PAD
5/6 📌 Conclusion: The study reveals a significant shift in PAD treatment towards endovascular techniques, especially in OBLs.
Is this the future of PAD management?
Explore the study: doi.org/doi:10.1016...
#VascularIntervention #MedicalInnovation
Is this the future of PAD management?
Explore the study: doi.org/doi:10.1016...
#VascularIntervention #MedicalInnovation
January 13, 2025 at 8:56 PM
5/6 📌 Conclusion: The study reveals a significant shift in PAD treatment towards endovascular techniques, especially in OBLs.
Is this the future of PAD management?
Explore the study: doi.org/doi:10.1016...
#VascularIntervention #MedicalInnovation
Is this the future of PAD management?
Explore the study: doi.org/doi:10.1016...
#VascularIntervention #MedicalInnovation
5/6 📌 Conclusion: Laser atherectomy-thrombectomy offers a potentially viable primary treatment option for ALI with promising outcomes.
Explore the full study for in-depth data: doi.org/doi:10.1016...
#VascularIntervention #MinimallyInvasive #MedTwitter
Explore the full study for in-depth data: doi.org/doi:10.1016...
#VascularIntervention #MinimallyInvasive #MedTwitter
January 4, 2025 at 4:15 PM
5/6 📌 Conclusion: Laser atherectomy-thrombectomy offers a potentially viable primary treatment option for ALI with promising outcomes.
Explore the full study for in-depth data: doi.org/doi:10.1016...
#VascularIntervention #MinimallyInvasive #MedTwitter
Explore the full study for in-depth data: doi.org/doi:10.1016...
#VascularIntervention #MinimallyInvasive #MedTwitter
4/5 📌 Conclusion: Multivariate analysis emphasizes that anatomical staging, mobility status, and CKD could significantly impact wound development in Rutherford category IV PAD patients post-endovascular therapy
Full study here: doi.org/doi:10.1186...
#VascularIntervention
Full study here: doi.org/doi:10.1186...
#VascularIntervention
January 3, 2025 at 7:40 PM
4/5 📌 Conclusion: Multivariate analysis emphasizes that anatomical staging, mobility status, and CKD could significantly impact wound development in Rutherford category IV PAD patients post-endovascular therapy
Full study here: doi.org/doi:10.1186...
#VascularIntervention
Full study here: doi.org/doi:10.1186...
#VascularIntervention
2/5 Study Overview:
🔹 25 patients, age 61±10 years, 44% female
🔹 PVS technical success in all cases!
🔹 Serum albumin, Child-Pugh scores, and ALBI scores evaluated before & after PVS.
#LiverSurgery #VascularIntervention
🔹 25 patients, age 61±10 years, 44% female
🔹 PVS technical success in all cases!
🔹 Serum albumin, Child-Pugh scores, and ALBI scores evaluated before & after PVS.
#LiverSurgery #VascularIntervention
December 29, 2024 at 7:05 PM
2/5 Study Overview:
🔹 25 patients, age 61±10 years, 44% female
🔹 PVS technical success in all cases!
🔹 Serum albumin, Child-Pugh scores, and ALBI scores evaluated before & after PVS.
#LiverSurgery #VascularIntervention
🔹 25 patients, age 61±10 years, 44% female
🔹 PVS technical success in all cases!
🔹 Serum albumin, Child-Pugh scores, and ALBI scores evaluated before & after PVS.
#LiverSurgery #VascularIntervention
5/6 📌 Conclusion: While particle type didn't affect biomarker levels post-TACE, miR-34a could emerge as a predictive tool for clinical outcomes in HCC treatments.
🔗 Dive into the full study here: doi.org/doi:10.1007...
#ClinicalResearch #MedTwitter #VascularIntervention
🔗 Dive into the full study here: doi.org/doi:10.1007...
#ClinicalResearch #MedTwitter #VascularIntervention
Tumor Suppressor miR-34a: Potential Biomarker of TACE Response in HCC
CardioVascular and Interventional Radiology - TACE induces variable systemic effects by producing factors that promote inflammation, oncogenesis, and angiogenesis. Here we compare concentrations of...
link.springer.com
December 21, 2024 at 4:47 PM
5/6 📌 Conclusion: While particle type didn't affect biomarker levels post-TACE, miR-34a could emerge as a predictive tool for clinical outcomes in HCC treatments.
🔗 Dive into the full study here: doi.org/doi:10.1007...
#ClinicalResearch #MedTwitter #VascularIntervention
🔗 Dive into the full study here: doi.org/doi:10.1007...
#ClinicalResearch #MedTwitter #VascularIntervention
4/5 📌 Conclusion: The IVUS-guided reentry and TD technique potentially enhance success in challenging peripheral CTO cases, providing a viable solution when bidirectional approaches aren't feasible.
Read full case details here: doi.org/doi:10.1186...
#VascularIntervention
Read full case details here: doi.org/doi:10.1186...
#VascularIntervention
December 17, 2024 at 1:04 PM
4/5 📌 Conclusion: The IVUS-guided reentry and TD technique potentially enhance success in challenging peripheral CTO cases, providing a viable solution when bidirectional approaches aren't feasible.
Read full case details here: doi.org/doi:10.1186...
#VascularIntervention
Read full case details here: doi.org/doi:10.1186...
#VascularIntervention
4/5 📌 Conclusion: PEDD shows promise in optimizing selective delivery of therapeutic agents into liver tumors, potentially enhancing treatment outcomes.
Dive into the full study here: doi.org/doi:10.1016...
#TargetedTherapy #VascularIntervention @TriSalusLifeSci
Dive into the full study here: doi.org/doi:10.1016...
#TargetedTherapy #VascularIntervention @TriSalusLifeSci
December 10, 2024 at 1:04 PM
4/5 📌 Conclusion: PEDD shows promise in optimizing selective delivery of therapeutic agents into liver tumors, potentially enhancing treatment outcomes.
Dive into the full study here: doi.org/doi:10.1016...
#TargetedTherapy #VascularIntervention @TriSalusLifeSci
Dive into the full study here: doi.org/doi:10.1016...
#TargetedTherapy #VascularIntervention @TriSalusLifeSci